Back to top
more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$71.21 USD

71.21
1,484,211

-0.73 (-1.01%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $71.19 -0.02 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (170 out of 252)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain Syneos Health (SYNH) For Now

by Zacks Equity Research

Investors are optimistic about Syneos Health's (SYNH) better-than-expected earnings and robust segmental performance.

Reasons to Retain Catalent (CTLT) Stock in Your Portfolio

by Zacks Equity Research

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.

Nevro's (NVRO) PDN Therapy Gets Noridian's Medicare Coverage

by Zacks Equity Research

Latest favorable coverage decision for Nevro's (NVRO) PDN Therapy by Noridian is expected to allow the former to serve a wider patient pool.

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.

Accuray's (ARAY) CyberKnife S7 System Gets Chosen by CARTI

by Zacks Equity Research

Accuray's (ARAY) CyberKnife S7 System gets selected by the CARTI medical care team, thereby offering better cancer care in Arkansas via expanded access to advanced technology.

Quest Diagnostics (DGX) Base Sales Recover Amid Price Woe

by Zacks Equity Research

Quest Diagnostics (DGX) raises 2022 guidance based on the continued rebound in base business and recent investments expected to accelerate growth.

Allscripts (MDRX) Inks Divestment Deal to Focus on Core Wing

by Zacks Equity Research

Constellation Software will purchase the net assets of Allscripts' (MDRX) Hospitals and Large Physician Practices business segment via its wholly-owned subsidiary.

Here's Why You Should Retain West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

Bio-Rad's (BIO) Product Launches Aid Growth, Global Arm Strong

by Zacks Equity Research

Bio-Rad's (BIO) Diagnostics business registers growth across all its product lines, driven by the recovery of routine testing.

Alcon (ALC) Expands in the U.S. With New Clareon IOLs Launch

by Zacks Equity Research

With the latest launch, Alcon's (ALC) Clarion Monofocal, Clareon PanOptix, Clareon PanOptix Toric, Clareon Vivity and Clareon Vivity Toric IOLs are now available in the United States.

Merit Medical's (MMSI) Product Included in FDA's Program

by Zacks Equity Research

Receipt of the Breakthrough Device Designation for Merit Medical's (MMSI) Embosphere Microspheres is expected to improve patient outcome.

Henry Schein (HSIC) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Henry Schein (HSIC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Here's Why You Should Retain Chemed (CHE) Stock For Now

by Zacks Equity Research

Investors are optimistic about Chemed's (CHE) better-than-expected earnings and robust performance by the Roto-Rooter arm.

Here's Why You Should Retain SmileDirectClub (SDC) For Now

by Zacks Equity Research

Investors are optimistic about SmileDirectClub's (SDC) strategic collaborations and product launches.

Here's Why You Should Hold on to Stryker (SYK) Stock for Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure remains a concern.

PacBio (PACB) Supports SickKids With Sequencing Technology

by Zacks Equity Research

PacBio (PACB) to help SickKids in detecting potential genetic causes of a range of medical and developmental conditions.

AmerisourceBergen (ABC) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about AmerisourceBergen's (ABC) strength in its World Courier business.

Catalent's (CTLT) New Tie-Up to Provide Better Patient Access

by Zacks Equity Research

Catalent's (CTLT) latest collaboration is expected to enable it to provide customers access to the TFF technology.

ResMed's (RMD) SaaS Arm Strength Aids Growth, Supply Woes Stay

by Zacks Equity Research

ResMed's (RMD) growing focus to expand in the high-growth international markets is an added upside.

Medtronic (MDT) to Gain From New Reimbursement Program for CGM

by Zacks Equity Research

Ontario government's new comprehensive reimbursement program for CGM will enhance access to Medtronic's (MDT) integrated CGM technology for type 1 diabetes patients.

Here's Why You Should Invest in Bio-Rad (BIO) Stock Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad (BIO) on solid recovery in most of its key global markets as well as an uptick in demand for COVID-related products.

Dexcom's (DXCM) CGM Gets FDA's Breakthrough Device Designation

by Zacks Equity Research

Dexcom's (DXCM) CGM's use in the hospital setting is likely to be more effective in glycemic management and improved patient outcomes.

Cooper Companies (COO) Q1 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Cooper Companies' (COO) fiscal first-quarter earnings reflect solid segmental performance.

Bruker (BRKR) to Improve Spatial Biology With New Launch

by Zacks Equity Research

Bruker's (BRKR) acquired company, Canopy Biosciences, introduced its next generation of ChipCytometry instrumentation for spatial biology.

New Strong Buy Stocks for March 4th

by Zacks Equity Research

BELFB, HSIC, LAD, MRC, and PPC have been added to the Zacks Rank #1 (Strong Buy) List on March 4, 2022.